A carregar...
Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials
Nintedanib is a tyrosine kinase inhibitor used to treat idiopathic pulmonary fibrosis (IPF). We investigated the cardiovascular safety of nintedanib using pooled data from the TOMORROW and INPULSIS trials. Cardiovascular events were assessed post hoc in patients with a history of atherosclerotic car...
Na minha lista:
| Publicado no: | Eur Respir J |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
European Respiratory Society
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6766682/ https://ncbi.nlm.nih.gov/pubmed/31285303 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/13993003.01797-2018 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|